Recruiting

4

550

 

Patients with bone and soft tissue sarcoma who had IV-degree bone marrow suppression in previous chemotherapy did not receive Turacilli for preventive treatment. ;Patients with bone and soft tissue sarcoma who have experienced IV-degree bone marrow inhibition in chemotherapy should receive trarasili (240 mg/m2, intravenous administration within 4 hours before chemotherapy, and the number of days of medication is determined according to the number of days of chemotherapy) before the next chemotherapy. ;Patients with bone and soft tissue sarcoma will not receive prophylactic treatment until they plan to receive a high-risk chemotherapy regimen. ;Before patients with bone and soft tissue sarcoma are proposed to receive high-FN-risk chemotherapy, trarasili (240 mg/m2, intravenous administration within 4 hours before chemotherapy, and the number of days of medication is determined according to the number of days of chemotherapy) for preventive treatment.

Affiliated Sixth People's Hospital, Shanghai Jiaotong University; Affiliated Sixth People's Hospital, Shanghai Jiaotong University, Self-finance

Bone and soft tissue sarcoma